KRM Ayurveda IPO opens for subscription on January 21, 2026, and closes on January 23, 2026, raising ₹77.49 crore through a fresh issue listed on NSE SME. The integrated Ayurvedic healthcare provider manages 6 hospitals and 5 clinics specializing in chronic conditions like kidney disorders, liver cirrhosis, diabetes, and arthritis, with GMP-certified manufacturing of wellness products. Funds target working capital, telemedicine infrastructure, and debt reduction. KRM Ayurveda IPO aligns with surging wellness demand and integrative medicine trends.
₹22
₹135
₹172.10
Expert Opinions
Market sentiment for KRM Ayurveda IPO displays mixed views among SME investors, attracted by wellness trends yet wary of aggressive pricing and earnings sustainability. Company strengths encompass GMP-certified production, specialized chronic disease treatments across 6 hospitals and 5 clinics, and telemedicine reach serving global patients with high repeat business. Risks highlight inconsistent historical revenues, regulatory scrutiny on Ayurvedic claims, dependency on skilled physicians, and competition from established players like Patanjali.
Valuation analysis for KRM Ayurveda IPO and year 2025 showcases Return on Equity (ROE) of 67.86%, ROCE of 43.33%, and Net Asset Value (NAV) of ₹1,602.40, reflecting exceptional profitability amid elevated multiples. Long-term investment perspective warrants selective allocation for healthcare diversification, contingent on sustained PAT margins and network expansion success.
Investor Considerations
KRM Ayurveda IPO investors need to review the company’s volatile yet recovering fundamentals, with FY 2025 revenue at ₹76.95 crore (up 13.88% YoY) and PAT soaring 254.83% to ₹12.10 crore, though prior years showed inconsistency. Ayurvedic healthcare sector outlook expands with wellness market projected to reach $70 billion by 2030, fueled by chronic disease prevalence and government support.
Valuation analysis for KRM Ayurveda IPO in 2025 features Price to Book Value of 0.08, PAT Margin of 15.80%, and Debt/Equity ratio of 1.31, presenting undervaluation alongside manageable leverage. Growth prospects include clinic/hospital network scaling and telemedicine enhancements targeting NRI patients. Risk factors comprise earnings sustainability doubts, regulatory approvals for claims, and physician dependency. Long-term investment goals suit diversified healthcare bets, while short-term pursuits risk SME pricing swings.
| Date | GMP | Trend |
|---|---|---|
| 28 Jan 2026 20.33 | ₹22 | Up |
| 27 Jan 2026 21.29 | ₹20 | Up |
| 26 Jan 2026 18.33 | ₹17 | Up |
| 22 Jan 2026 21.12 | ₹16 | Up |
| 21 Jan 2026 20.28 | ₹12 | Down |
| 19 Jan 2026 20.30 | ₹20 | --- |
| 18 Jan 2026 13.13 | ₹20 | --- |
FAQs
The Grey Market Premium showed moderate accuracy in predicting KRM Ayurveda IPO’s listing performance. With a final GMP of ₹22, it projected a premium of 16.30% over the issue price of ₹135. The stock listed at ₹172.10, delivering a gain of 27.48%. This resulted in a moderate prediction error of 11.18%, where the GMP correctly signaled a positive listing but underestimated the actual gain, reflecting fair reliability in this case.
KRM Ayurveda IPO Current GMP is ₹22.
KRM Ayurveda IPO Expected Returns is 16.30%.
KRM Ayurveda IPO estimated listing price is ₹157.